BCDA BioCardia, Inc.
Listings ·
Nasdaq granted BioCardia until October 7, 2026 to regain compliance. The company says at-the-market sales with H.C. Wainwright & Co. brought net proceeds of $4.9 million and that it believes equity now exceeds $2.5 million.
Nasdaq staff told BioCardia in writing that it again meets the Equity Rule, but the 8-K gives no equity figure and does not say how the gap was closed.
BioCardia says its stockholders' equity exceeds the $2.5 million Nasdaq minimum after two private placements, an offering with net proceeds of about $5.1 million and at-the-market sales. Nasdaq will keep monitoring the company.
The September 16 registration covered up to 2,800,000 shares at an assumed $2.27. On September 18 the final prospectus sold 4,800,000 shares with warrants at $1.25, for $6,000,000.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $5.0 million | $4.4 million |
| Net income (loss) | -$8.2 million | -$7.9 million |
| Cash from operations | -$7.4 million | -$7.9 million |
| Cash and equivalents | $2.5 million | $2.4 million |
Our latest story on this, dated Jun 12, 2026: "BioCardia believes it regained Nasdaq stockholders' equity compliance after at-the-market sales". The story links the filing or release it is based on. Read the story.
BioCardia, Inc. trades under the ticker BCDA on NASDAQ.
BioCardia, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for BioCardia, Inc. is 925741. Its filings are on SEC EDGAR.
15,138,782 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-12.
Our directory records BioCardia, Inc. under United States.
Our directory classifies BioCardia, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for BioCardia, Inc. is US09060U6064.
aibio.space lists BioCardia, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
BioCardia, Inc. reported a net loss of $8.2 million for the fiscal year ended Dec 31, 2025, and used $7.4 million of cash in operations, per its annual report to the SEC.
$5.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
$4.1 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on BioCardia, dated Jun 12, 2026: "BioCardia believes it regained Nasdaq stockholders' equity compliance after at-the-market sales". Nasdaq granted BioCardia until October 7, 2026 to regain compliance. The company says at-the-market sales with H.C. Wainwright & Co. brought net proceeds of $4.9 million and that it believes equity now exceeds $2.5 million. Source.
From our story of Jun 12, 2026: The company lists its ability to raise funding, to continue as a going concern and to keep its Nasdaq Capital Market listing among its stated expectations. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio